Sugi Predict

Sugi Predict / Compounds / SCHEMBL1645467

SCHEMBL1645467

SCHEMBL1645467

Cc1cc(C)nc(N2CCCN(c3ccc(NC(=O)C(=O)c4c(C5CCCC5)cc5ccccn45)cc3)CC2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.37
▸ ALDH1A1 P00352 6/20 0.37
▸ LMNA P02545 5/20 0.37
▸ HTT P42858 2/20 0.37
▸ RAB9A P51151 6/20 0.37
▸ NPC1 O15118 4/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ GAA P10253 3/20 0.37
▸ NPSR1 Q6W5P4 3/20 0.37
▸ USP2 O75604 3/20 0.37
▸ PKM P14618 1/20 0.37
▸ SLC2A1 P11166 2/20 0.35
▸ KDM4E B2RXH2 4/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648063 0.99 MAPT (0.38) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL1646224 0.98 MAPT (0.38) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL1645168 0.98 MAPT (0.38) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL2232068 0.95 MAPT (0.39) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL1647637 0.95 MAPT (0.40) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL1644920 0.92 MAPT (0.42) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL1646827 0.92 RAB9A (0.37) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL1644918 0.90 F13A1 (0.39) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL13439003 0.89 SLC27A1 (0.39) MAPTALDH1A1LMNAHTTRAB9A
SCHEMBL1644957 0.89 F13A1 (0.38) MAPTALDH1A1LMNAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 — — EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 — — US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 — — US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 — — EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 — — US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 MAPT 1771/4885ALDH1A1 2813/4885LMNA 3870/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 MAPT 2950/4885ALDH1A1 318/4885LMNA 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.